Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $8.52 Average PT from Analysts

Posted by on Jul 7th, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $8.5222.

Several analysts have recently weighed in on ALLO shares. Piper Sandler lifted their price target on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, March 13th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 13th. Citizens Jmp increased their price target on shares of Allogene Therapeutics from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Tuesday, April 14th. Jefferies Financial Group lifted their price objective on shares of Allogene Therapeutics from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Robert W. Baird increased their target price on shares of Allogene Therapeutics from $7.00 to $9.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th.

Check Out Our Latest Report on Allogene Therapeutics

Institutional Trading of Allogene Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new position in shares of Allogene Therapeutics during the first quarter valued at about $85,000. Goldman Sachs Group Inc. increased its position in shares of Allogene Therapeutics by 177.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after acquiring an additional 3,747,397 shares during the period. Jane Street Group LLC raised its stake in Allogene Therapeutics by 578.7% in the 1st quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after acquiring an additional 952,158 shares during the last quarter. Geode Capital Management LLC raised its stake in Allogene Therapeutics by 13.0% in the 2nd quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock worth $4,289,000 after acquiring an additional 435,389 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Allogene Therapeutics by 14.0% during the 2nd quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock worth $237,000 after acquiring an additional 25,628 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $2.02 on Thursday. The stock has a 50-day simple moving average of $2.08 and a two-hundred day simple moving average of $2.03. The firm has a market capitalization of $698.93 million, a PE ratio of -2.63 and a beta of 0.46. Allogene Therapeutics has a 52-week low of $0.98 and a 52-week high of $4.46.

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Equities analysts forecast that Allogene Therapeutics will post -0.7 earnings per share for the current fiscal year.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.

Read More

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.